Introduction
An in-depth knowledge of the indications, contraindications, and limitations of several imageguided therapies, in addition to a detailed understanding of individual vascular anatomy and flow dynamics, is necessary in choosing an appropriate treatment option in patients with complicated portal hypertension.
Transjugular intrahepatic portosystemic shunt (TIPS) placement has a recognized role in the management of variceal hemorrhage and intractable ascites. Several alternate image-guided modifications may be considered for patients in whom TIPS placement has failed or is contraindicated (absolute or relative). Data for some of these alternate procedures suggest equal or improved outcome compared with TIPS placement in selected patients-for example, balloonoccluded retrograde transvenous obliteration (BRTO) for gastric varices (1) (2) (3) (4) . Partial splenic embolization (PSE), either alone or in combination with other techniques, has proved beneficial in case series and nonrandomized studies on the management of variceal hemorrhage (5) . Imageguided embolization is a useful alternative to TIPS placement in patients with ectopic varices (6) , which may bleed even when portal venous pressure is low (7) (8) (9) .
In this article, we discuss image-guided alternatives to TIPS placement in terms of pathoanatomy, indications and contraindications, and technical considerations.
Portal Hypertension
Portal hypertension is defined as a portal pressure gradient (the difference in pressure between the portal veins and the hepatic veins) of 5 mm Hg or greater. It is generally classified as prehepatic, hepatic, or posthepatic, depending on the location of the primary block to blood flow (Table 1 ). In hepatic (sinusoidal) cirrhosis, portal hypertension results from both increased resistance to portal flow and increased portal venous inflow. Increased resistance is both structural (due to fibrosis and regenerative nodules) and dynamic (increased hepatic vascular tone due to endothelial dysfunction mediated by increased endothelin-1 [ET-1] production and decreased nitric oxide bioavailability) (10) .
When the portal pressure gradient exceeds a certain threshold, collateral vessels develop at sites of communication between the portal and systemic circulations and decompress or shunt the portal flow into the systemic circulation. This process is modulated by angiogenic factors. In addition, portal venous inflow increases as a result of splanchnic vasodilatation and increased cardiac output. Increased portal flow maintains and exacerbates portal hypertension (11) . In severe portal hypertension, blood flow may change direction in the portal vein from hepatopedal to hepatofugal and may reverse in the superior mesenteric vein, leading to the formation of mesenteric varices.
Wedged hepatic venous pressure (a transducer measurement obtained through either a wedged end-hole catheter or an occlusion balloon in a distal hepatic vein branch) is the pressure transmitted through the sinusoids from the portal vein. In patients with intra-and posthepatic obstruction, the HVPG (wedged pressure-free [unoccluded] hepatic venous pressure) is an accurate indirect measurement of portal pressure. It has been validated in multiple clinical settings as an independent predictor for adverse outcome, including the risk of developing varices, ascites, and clinical decompensation in cirrhotic patients (12) . Changes in HVPG can be used as a surrogate for a patient's portal pressure response to pharmacologic therapy, since bleeding risk in chronic HVPG responders is extremely low. For patients with acute variceal bleeding, an HVPG of 20 mm Hg or greater independently predicts a poor outcome and may help identify high-risk patients in whom early use of TIPS placement is preferable to combined pharmacologic and endoscopic therapy (12) .
In prehepatic obstruction, portal blood flow is reduced before it reaches the hepatic sinusoids, such that the wedged hepatic venous pressure does not reflect the portal pressure (Table 1) . Portal vein thrombosis (PVT) is the classic example, but other causes of presinusoidal portal hypertension, including "downhill" varices (from obstruction of the superior vena cava with or without obstruction of the azygos vein) and the presence of a competing portosystemic shunt, should also be considered in patients who present with acute variceal hemorrhage and a normal hepatic pressure gradient.
Portosystemic Collateral Vessels
Clinically significant esophageal and rectal varices are usually visible endoscopically, but paraesophageal and gastric varices may be less clearly, or incompletely, identified (Fig 1, Table 2 ). Ectopic varices outside the cardioesophageal region may be identified at endoscopic ultrasonography (US) but are often identified only at cross-sectional imaging. Bleeding from ectopic varices outside the gastroesophageal region is uncommon, accounting for 5% or fewer of all cases of variceal bleeding. Duodenal varices account for one-third of these cases; other sites of involvement include the small bowel, colon, bile duct, stomas, retroperitoneum, ovaries, vagina, and bladder. Multiplanar portal venous phase computed tomography (CT) and magnetic resonance (MR) imaging are now readily available in most radiology departments and facilitate identification of these complex collateral pathways (13, 14) .
Interventions in Portal Hypertension
The major sequelae of portal hypertension include variceal hemorrhage, hypersplenism, hepatogenic ascites, and hydrothorax. The primary goal in the treatment of portal hypertension is reduction in portal pressure (Table 3 ). The hemodynamic effects of portal hypertension may be modified through the use of certain systemic drugs. Parenteral splanchnic vasoconstrictors such as vasopressin and somatostatin decrease mesenteric arterial flow, thereby decreasing portal venous inflow. Oral nonselective beta-adrenergic blockers, such as propranolol and nadolol, affect portal flow by means of both b 1 blockade (reduction of cardiac output) and b 2 blockade (splanchnic vasoconstriction). Nitrates, adrenergic inhibitors, and angiotensin blockers act by inducing intrahepatic vasodilatation and may have a synergistic effect. The disadvantages of these agents include relatively common contraindications and side effects (fatigue and shortness of breath), which may preclude treatment or require discontinuation in 15%-20% of patients. In patients with medium-sized or large esophageal varices, either nonselective beta-blockers or endoscopic variceal ligation can be used; a meta-analysis of high-quality, randomized, controlled trials has shown equivalent efficacy and no differences in survival (15) . Patients who do not respond to these measures should be considered for image-guided therapy. Depending on the underlying cause, it may be possible to reduce portal pressure by establishing or reestablishing patency in an occluded vein, creating a shunt to allow bypass flow, or decreasing inflow from the arterial side. When it is not possible to achieve this primary goal, alternate procedures may be used to palliate or control symptoms related to portal hypertension, such as the occlusion of portosystemic collateral vessels or the removal of transudate-exudate fluid from serosal spaces ( Table 3) .
Selection of Procedure and Access
Choosing the appropriate procedure for an individual patient should take into account the following considerations: (a) etiology; (b) patient presentation; (c) the patient's medical condition and comorbidities (liver status, presence of cardiac or renal disease); (d) vascular anatomy and pathoanatomy (including access route, prior surgery, and location of varices); and (e) local expertise and available resources.
Access to the portal venous system for intervention can typically be gained through a percutaneous transjugular or transhepatic approach.
Other approaches may be required in unusual circumstances, such as neck and hepatic vein occlusion, extensive hepatic malignancy and polycystic disease, and portal vein occlusion. Access routes through the IVC, spleen, ectopic varices, and native portosystemic collateral vessels (including the umbilical vein) are well recognized (Fig 2) . Direct jejunal vein puncture by means of laparotomy has been successfully used to access bleeding jejunal varices (16) . Rozenblit et al (17) reported good success in a series of 61 patients who underwent intrahepatic portosystemic shunt placement with a combination of transfemoral access to the hepatic vein and transmesenteric access to the portal system by means of a minilaparotomy. The authors found the method to be safer and more efficient than the transjugular approach (17) .
TIPS: Indications, Limitations, and Challenges
TIPS is a transjugular portosystemic shunt created within the liver parenchyma between the hepatic vein and the portal vein to achieve a portosystemic gradient of less than 12 mm Hg. Several excellent reviews of the technical aspects of covered TIPS placement and management of shunt dysfunction have been published (18) (19) (20) . In pediatric patients, the technique is similar, although carbon dioxide (CO 2 ) venography is not recommended for very young patients due to the risk of hepatic laceration; and balloon-expandable bare or uncovered stents are preferred, allowing further dilation during the growth of the child (21) . Indications for TIPS placement include uncontrollable variceal bleeding, recurrent variceal bleeding in patients who have failed endoscopic and medical therapy, refractory ascites or hydrothorax, acute gastropathy, hepatorenal syndrome, Budd-Chiari syndrome, and hepatopulmonary syndrome.
Absolute contraindications to TIPS placement include right heart failure and pulmonary arterial hypertension, severe polycystic liver disease, uncontrolled systemic infection or sepsis, liver abscess, unrelieved biliary obstruction, and portal hypertension from arterioportal fistula (APF).
Relative contraindications include severe liver failure (Child-Pugh class C cirrhosis, Model for End-Stage Liver Disease (MELD) score >22, serum bilirubin level >3 mg/dL), for which TIPS placement has an unclear survival benefit, and preexisting encephalopathy. Other relative contraindications include hepatoma (especially if central), obstruction of hepatic veins, PVT, hepatic vein thrombosis, severe coagulopathy (international normalized ratio [INR] >5), thrombocytopenia (<20,000/cm 3 ), moderate pulmonary hypertension, and severe stenosis or occlusion of the celiac or hepatic artery (22) .
It is now well recognized that, compared with intermittent large-volume paracentesis, TIPS placement significantly improves transplant-free survival in cirrhotic patients with refractory ascites (23) . For esophageal variceal bleeding, TIPS placement also compares favorably with combined medical and endoscopic therapy (24, 25) . For patients with Budd-Chiari syndrome, TIPS placement is associated with less morbidity than is surgery. In published case series, ascites control following TIPS placement for Budd-Chiari syndrome approaches 100%, and improvement in liver function can eliminate the need for transplantation (26, 27) . The benefits of TIPS are less clear for gastric varices (the portosystemic pressure gradient may be low or even normal due to shunting) and for ectopic varices, which are not specifically targeted and have high recurrent bleeding rates (7).
Safe, accurate, and timely puncture of the portal vein is desirable during a TIPS procedure but can be challenging. Cross-sectional imaging with postprocessing, such as thick-slab venous phase maximum intensity projection of CT data, can help identify anatomic variations and optimal angles for puncture. The success rate for intraprocedural portal vein visualization with CO 2 wedged or balloon-occluded hepatic venography is approximately 90%. Opacification of the portal vein can also be achieved directly by means of percutaneous transhepatic portal vein or direct variceal puncture, or by means of indirect portal venography with either superior mesenteric arteriography or CO 2 splenoportography. Several modifications have been described that can facilitate TIPS placement in patients with challenging vascular anatomy. A left jugular vein access site has potential technical advantages, including a possible straighter course to the preferred target portal vein site. A recent series reported no difference in complication rates for TIPS placement performed with a right-or left-sided jugular approach, whereas technical success improved with the left jugular approach and greater physician experience with TIPS procedures (28) .
In some patients, direct portocaval puncture, essentially creating a side-to-side portocaval shunt, may be required when the hepatic veins are occluded, as in Budd-Chiari syndrome or in the presence of unfavorable hepatic venous anatomy due to a shrunken right hepatic lobe with a transverse or cephalic course of the hepatic vein.
Portocaval puncture can be performed with fluoroscopy alone using a fine-needle system (Angiodynamics, Queensbury, NY) with a combined transhepatic and transjugular "gunsight" technique (29, 30) . US guidance can be used for percutaneous transhepatic puncture through the portal vein to the IVC with snaring of a guidewire via a jugular vein puncture. This technique has been shown to be useful in patients with Budd-Chiari syndrome (31, 32) . These patients typically have an enlarged caudate lobe, complicating access to the portal vein and causing intrahepatic caval compression. The accuracy of US-guided puncture of the intrahepatic IVC may be enhanced with use of a caval balloon (Fig 3) . CT-and endoscopic US-guided puncture have also been described (33) .
Direct intrahepatic portocaval shunt (DIPS) placement is a further modification of the TIPS procedure in which intravascular US guidance is used for puncture from the intrahepatic IVC after TIPS or whether it should be reserved for certain anatomic subsets, such as patients with previous or recent bleeding, a persistently elevated portosystemic pressure gradient, or gastric varices; or used to reduce the risk of chronic liver failure in patients with large shunts and a low portosystemic gradient by improving hepatic portal perfusion. An Amplatzer vascular plug (AGA Medical, Golden Valley, Minn) may be useful for the occlusion of large gastric varices and spontaneous gastrorenal or splenorenal shunts (35) (36) (37) .
Recanalization of the Hepatic Vein
Budd-Chiari syndrome is characterized by venous outflow obstruction at the level of the hepatic veins, IVC, or right atrium. Recanalizing the hepatic vein or IVC by means of balloon angioplasty or stent placement can relieve hepatic congestion and prevent progression to irrevers- to the portal vein through the caudate lobe. The shunt is completed with a polytetrafluoroethylene-covered stent (Viatorr; W.L. Gore, Flagstaff, Ariz), or a balloon-expandable stent if the patient is at risk for encephalopathy (34) .
In some interventional radiology practices, DIPS placement has largely replaced the TIPS procedure, with reported fluoroscopy time routinely under 10 minutes and total procedure time routinely less than 1 hour in experienced hands (34) . A coaxial sheath technique can be used to facilitate DIPS placement in patients with a very large IVC, caval tortuosity, or massive ascites.
The DIPS procedure can be extremely helpful in patients with challenging anatomy, such as inadequacy, thrombosis, or calcification of the portal vein or unsuitable parenchymal tract due to hepatocellular carcinoma, and can also be used as an alternative to occluded TIPS revision (34) .
It is unclear whether concomitant variceal embolization should be performed routinely ible liver damage. Li et al (38) reported satisfactory midterm outcomes (primary and secondary patency rates of 76% and 84%, respectively, at 2 years) for balloon angioplasty for hepatic vein occlusion in patients with Budd-Chiari syndrome. The technical success rate was 91% (92 of 101 patients), with a higher rate of technical failure in patients with long-segment vein occlusion, although stents were used in only two patients (38) .
Transabdominal US may be used to guide a catheter and wire through a transjugular liver biopsy cannula (positioned in the IVC) across ostial or short segmental occlusions. This technique obviates percutaneous transhepatic puncture, drainage of ascites, and normalization of bleeding parameters (39). 
Recanalization of the Portal Vein and Its Tributaries
Extrahepatic obstruction of the portal vein or its branches accounts for 5%-10% of all cases of portal hypertension (higher in children). The cause of obstruction can be benign or malignant, and patients usually present with variceal bleeding, ascites, or abdominal pain. Recanalization of the blocked vein by means of angioplasty and stent placement will reduce these symptoms and is typically performed using either a transjugular or percutaneous transhepatic (Figs 4, 5) approach (40, 41) . Placement of an additional TIPS may be necessary to prevent thrombosis if blood flow through the recanalized channel is slow or the portosystemic gradient after recanalization is greater than 12 mm Hg (42). Tuite et al (43) reported the use of the transsplenic route in three patients with chronic PVT who underwent successful portal vein-splenic vein recanalization. Two patients underwent concomitant TIPS placement and variceal embolization with conventional catheter and wire techniques (43) . (45) classified APFs into small peripheral type 1 (asymptomatic, typically resolving spontaneously), large central type 2, and congenital type 3. Small APFs are rarely of concern (except perhaps in patients being considered for hepatic artery chemoembolization or radioembolization). Types 2 and 3 may require surgical or interventional treatment. The preferred treatment is transarterial embolization of the feeding artery using coils, glue, or the Amplatzer vascular plug (AGA Medical) (46) . In general, coils can be used successfully in simple arterioportal shunts (with a single feeding artery), whereas more complex shunts, with multiple feeding arteries due to cirrhosis, tumor, or previous surgery, typically require a liquid or particle agent to abolish the shunt.
Embolization of APF
APFs are a rare cause of portal hypertension (44). They may be congenital or secondary to trauma, surgery, percutaneous procedures such as biopsy, or liver tumors. Most APFs are asymptomatic, although clinical symptoms such as gastrointestinal bleeding, ascites, and congestive heart failure can occur. Decades may elapse between fistula formation and detection. Guzman et al
Partial Splenic Embolization
Hypersplenism and platelet sequestration may contribute to thrombocytopenia in patients with cirrhosis and portal hypertension. Endoscopic variceal ligation may be effective but does not address the underlying portal hypertension. Although a portosystemic shunt reduces the risk of hemorrhage by reducing the underlying portal pressure, it may not be suitable in all patients (eg, patients with advanced liver dysfunction and encephalopathy or PVT). Open or laparoscopic splenectomy has been proposed but has not gained widespread acceptance because of the high risk of complications (up to 10%), especially of PVT. Furthermore, there is a subset of patients in whom esophagogastric varices (short gastric and gastroepiploic veins) may develop as a consequence of isolated splenic vein thrombosis (eg, secondary to pancreatitis), a condition known as sinistral portal hypertension. In such patients, TIPS placement should not be performed because splenic artery embolization or splenectomy can successfully eliminate the source of gastric varices.
PSE is performed to diminish inflow of blood into the portal vein, with secondary reduction in portal pressure (Figs 4, 6 ). This procedure achieves reduction in splenic size, improvement in hypersplenism-induced thrombocytopenia due to decreased splenic sequestration, increased white cell count due to decreased splenic pooling, and increased red blood cell count attributed to increased erythrocyte survival time (5) .
PSE can result in a variable decrease in portal pressure gradient in patients with cirrhosis and portal hypertension; however, changes in variceal flow rather than changes in portal pressure per se are thought to be more predictive of outcome. A spleen-to-liver volume ratio greater than 0.5 based on CT findings is reported to be a positive predictor of a decrease of over 20% in portal pressure gradient, and this cutoff value can be used to identify patients who may benefit from obliteration of splenic artery inflow as a method of decreasing portal hypertension (47) . Embolization may be performed alone or in combination with other interventions, such as endoscopic ligation or retrograde transvenous variceal obliteration (48) (49) (50) . Hepatofugal flow is regarded as a contraindication to PSE due to the increased risk of PVT. A systematic review from 2007 points to a lack of sufficient high-quality evidence to allow an evidence-based evaluation of PSE in achieving control of variceal hemorrhage (5).
Xu et al (48) reported their experience with endoscopic variceal ligation and PSE in 41 patients. Esophageal varices and hypersplenism were well controlled, without recurrent hemorrhage (mean follow-up interval, 9.9 months), and there was a significant reduction in flow rate and maximum flow velocity in the main portal vein. Postembolization splenic abscess occurred in one patient, and another patient died of a pulmonary embolus (48) . In a nonrandomized study, Chikamori et al (51) performed PSE 7-14 days before BRTO in 14 patients. The 3-year cumulative occurrence rate of esophageal varices was 9%, compared with 45% in a similar group who underwent BRTO alone (51). Pålsson et al (52) reviewed 26 patients who underwent a total of 52 PSE procedures, mainly for thrombocytopenia due to bleeding from esophageal varices. The mean hemoglobin value, leukocyte count, and platelet count increased significantly after partial embolization, and the frequency of bleeding from esophageal varices decreased significantly. One patient died as a result of severe hepatic insufficiency, and another patient died of complete splenic infarction with abscess, total PVT, and cardiac insufficiency (52) .
Embolic agents for PSE include polyvinyl alcohol particles, embospheres, and absorbable gelatin sponge (Gelfoam; Pharmacia Upjohn, Kalamazoo, Mich). Concomitant antibiotics or embolic agents soaked in antibiotic solutions may reduce the risk of splenic abscess. The efficacy of PSE for thrombocytopenia is dependent on shrinking the parenchymal volume by at least 50% (53) . Embolization of over 70% of splenic volume may increase the risk of complications, including pleural effusion and abscess (53) . In particular, avoiding the cranial aspect of the spleen may reduce the likelihood of an inflammatory reaction that might induce diaphragmatic irritation and pleural effusion. Postembolization symptoms may require hospitalization (42) .
Percutaneous Transhepatic Variceal Embolization
Percutaneous transhepatic variceal embolization (PTE) was described in 1974 by Lunderquist and Vang (54) for the treatment of intractable variceal bleeding. Although this initially appeared to be a highly effective procedure, successfully controlling acute bleeding in 70%-90% of patients, recurrent bleeding was seen in 10%-60% of cases, since the underlying portal hypertension was unaffected. A failure rate of up to 9% was reported, particularly in patients with PVT or small livers with marked ascites (55) , and PTE itself was implicated in inducing transient PVT in up to 36% of patients (56) . Some authors recommend the prophylactic administration of subcutaneous low-molecular-weight heparin for 5-7 days after PTE for this reason (57) . Despite these reservations, PTE remains safe and effective for the treatment of special types of varices with portal hypertension and may be considered in cases in which TIPS placement fails or is contraindicated; and in patients with (a) bleeding ectopic varices, including rectal (Fig 7) , stomal (Fig 8) , and duodenal (Fig 9) been used, including coils, cyanoacrylate glue, absorbable gelatin sponge, and sclerosants such as 50% dextrose, ethanol, sodium tetradecyl sulfate (Sotradecol; Angiodynamics, Queensbury, NY), and ethanolamine.
In 2007, Chikamori et al (59) reported successful PTE in 13 patients with use of a variety of complex shunts and varices. To our knowledge, there have been no randomized controlled trials comparing TIPS placement and PTE in the management of bleeding ectopic varices, but available data suggest that recurrent bleeding can occur in 25%-40% of cases despite hemodynamic targets being achieved (60) . The use of adjuvant embolization following TIPS placement appears to result in greater efficacy (60) .
BRTO of Varices
The behavior of gastric varices varies depending on their location. Most isolated fundal or fundalcardiac varices drain through a developed gastrorenal shunt, such that the portal pressure in such patients is quite low. Tripathi et al (61) showed that a significant proportion of gastric varices bleed at a portal pressure gradient of 12 mm Hg or lower, and that TIPS placement improved mortality only in patients with gastric variceal bleeding at a portal pressure gradient greater than 12 mm Hg.
BRTO is a technique that was popularized in Japan for control of gastric varices (62, 63) . Technical feasibility requires a natural gastrorenal or gastrophrenic shunt (up to 95% of gastric varices), which is typically well demonstrated at contrastenhanced CT. The technique involves advancing a balloon catheter from the femoral or jugular vein into the outlet of the gastrorenal shunt-left adrenal vein. Following balloon occlusion of the shunt, a sclerosant (typically 5% ethanolamine oleate with lipiodol or iopamidol) is injected retrogradely to fill the gastric varices, either directly or through a coaxial microcatheter (Fig 10) (1,58) . If ethanolamine is unavailable, the use of other sclerosants such as alcohol, 50% dextrose, sodium tetradecyl sulfate, or an ethylene vinyl alcohol copolymer (Onyx, eV3-Endovascular) can be considered. An infusion of haptoglobin is commonly used to protect against renal dysfunction caused by ethanolamine-induced hemolysis. Balloon rupture is uncommon but may cause rapid migration of sclerosant, pulmonary embolism, or recurrent gastric variceal bleeding.
A detailed understanding of the venous anatomy and flow patterns is the most important factor in ensuring successful treatment. Hirota et al (63) classified gastric varices and collateral veins into five grades according to the results of adrenal venography during balloon occlusion in a series of 20 patients. In grade 1, gastric varices are well opacified with no evidence of collateral veins (such as inferior phrenic, hemiazygos, or pericardial veins). In grade 2, contrast material remains in the gastric varices for 3 minutes or more, with collateral veins small and few in number. In grade 3, contrast material fills the gastric varices only partially and disappears within 3 minutes, and collateral veins are medium sized to large and few in number. In grade 4, gastric varices are not opacified and there are many large collateral veins. In grade 5, the left adrenal vein cannot be occluded with the balloon catheter because of a very large gastrorenal shunt with rapid blood flow (63) . This classification system may help in selecting the optimum technique for BRTO (eg, additional or staged embolization, or combined with PSE or transhepatic embolization). The authors suggest that occlusion of collateral veins is essential for the obliteration of gastric varices higher than grade 2 (63).
Kiyosue et al (64) Additional techniques that can be considered in BRTO of complex shunts (Kiyosue type 2 or 3, B or C) include stepwise injection of the sclerosing agent, selective injection of the agent via a microcatheter (to decrease the volume of sclerosant required), coil embolization of the afferent gastric veins or collateral draining veins, doublecatheter technique (for collateral vessels that cannot be catheterized), double-balloon technique (for gastrocaval or inferior phrenic shunt) (65) , and BRTO performed with percutaneous transhepatic portal venous access or transileocolic venous access (Fig 11) (66) . Concomitant balloon occlusion of the splenic artery may improve distribution of sclerosant in the gastric varix and has the potential to improve outcome through more extensive thrombosis.
BRTO is considered by many investigators to be as effective as TIPS placement in controlling gastric variceal bleeding (1-3). Potential advantages of BRTO over TIPS placement include augmentation of portal blood flow, preserving or improving liver function in patients with a poor hepatic functional reserve, and prevention of encephalopathy (1, 2) . It has been suggested that patients with large gastric fundal varices bleed at a lower portal pressure than those with esophageal varices, due to a combination of shunt formation and large variceal size. In these patients, TIPS placement is less successful than in patients with esophageal varices (67) , and BRTO may be a particularly suitable treatment option (4) .
Occlusion of a gastrorenal shunt may aggravate existing esophageal varices or lead to the development of new varices and may result in PVT (3). Cho et al (68) reported that ascites developed or was aggravated in 82% of patients, and that the spleen showed enlargement in 56% of patients within 1 week of BRTO.
Cho et al (69) reported thrombus in major systemic or portal veins in 15% of 60 patients following BRTO. Interestingly, high-attenuation thrombus (n = 7), which was thought to represent iodized oil deposition, showed complete resolution at follow-up imaging, whereas lowattenuation thrombus (n = 2) was associated with late venous occlusion (69). Miyamoto et al (70) suggest that the elevated portal pressure seen immediately after BRTO returns to baseline after 4 weeks as alternate collateral vessels develop. Ninoi et al (2) followed up 78 patients (mean, 700 days) who had undergone BRTO. The 5-year gastric varices recurrence rate was 2.7%, and the 5-year bleeding rate was 1.5% (3.5% in patients with a history of bleeding before BRTO) (2) . Worsening of esophageal varices was observed in 37% of patients. Multivariate analysis demonstrated that the presence of esophageal varices before BRTO was a prognostic factor for worsening (2).
Tanihata et al (71) reported aggravation of esophageal varices in 11 of 19 patients (57%) 18 months after BRTO. The authors found that a portosystemic pressure gradient greater than 5 mm Hg was more strongly related to aggravation of esophageal varices than the presence of esophageal varices before BRTO.
Long-term results from BRTO are encouraging. In a study of 33 patients with initial bleeding from gastric varices, Hiraga et al (72) reported a 7-year cumulative worsening rate of esophageal varices of 52%. All patients were successfully managed endoscopically, with a recurrent bleeding rate of just 10% (72). Endoscopy demonstrated a large clot in the first part of the duodenum and several small ulcers in the second part. (a) CT angiogram is negative for pseudoaneurysm and active bleeding but demonstrates cavernous transformation of the portal vein with extensive periduodenal varices (arrow). A gas-containing peripancreatic collection ( * ) is also noted. Empirical gastroduodenal artery embolization was performed; however, the patient continued to require transfusion for ongoing melena and underwent repeat mesenteric arteriography (with negative results) 10 days after embolization. Following large-volume paracentesis, US was used to access the right gastroepiploic vein. (b) Venogram demonstrates extensive periportal varices (arrows). A total of 6 mL of a mixture of 2 mL of air, 2 mL of 3% tetradecyl sulfate, and 2 mL of lipiodol was injected through a 4-F Cobra glide catheter (Terumo, Somerset, NJ). This mixture partly filled the varices. More distal access was not possible due to vessel tortuosity. (c) Postsclerotherapy digital subtraction venogram shows no variceal filling and a patent gastroepiploic vein. The access tract was occluded using a Gelfoam (Pharmacia Upjohn) slurry. The bleeding ceased, and, although the patient had another episode of melena 4 months later, further intervention was not attempted.
Ectopic Varices: Percutaneous Access and Sclerotherapy
Stomal variceal bleeding can develop in patients with underlying cirrhosis and portal hypertension. Most patients are best treated with TIPS placement because this procedure addresses the underlying portal hypertension; however, stomal varices may bleed even when the transsinusoidal pressure is less than 12 mm Hg (7-9). For acute bleeding, transhepatic coil embolization of stomal varices has shown good results, although vessel recanalization or new varices formation may eventually mandate further intervention (Fig 8) (9) . Freehand (non-image-guided) sclerotherapy is not recommended due to high rates of stomal damage (9); however, more proximal access with image-guided embolization can be a useful alternative in patients with contraindications to TIPS placement (6) .
A thorough review of cross-sectional imaging findings is required to identify suitable veins. The use of US guidance to facilitate coil embolization or sclerotherapy of stomal varices has recently been reported (Fig 12) (6,73) . Other veins may occasionally provide access to the portal system. Even with a micropuncture set, however, percu taneous access may be challenging (Fig 13) . Mi nami et al (74) have reported a cutdown technique for access to the left superficial epigastric vein to perform BRTO for stomal varices, and Nakata et al (75) have recently used a similar access route for sclerotherapy of jejunal varices. If a sclerosant is used, fluoroscopy-guided compression over drainage veins can decrease early outflow into the systemic system.
Surgical Shunts
In addition to TIPS and DIPS placement, there are several surgical portosystemic shunt placement procedures such as portocaval, mesocaval, mesoportal, or distal splenorenal shunt placement that can be performed in patients with portal hypertension. Unlike the use of endoscopic therapy (sclerotherapy or banding) for prevention of recurrent variceal bleeding in patients with cirrhosis, there is no consensus as to which approach is preferable. A Cochrane review (76) of 22 randomized clinical trials evaluating 1409 patients found that all shunts resulted in a significantly lower recurrent bleeding rate, but at the expense of a higher incidence of encephalopathy. No survival advantage was demonstrated with any shunt. Most studies comparing surgical shunts with TIPS have found the rates of thrombosis, stent stenosis, and reintervention to be significantly higher in the "TIPS" group. However, there are comparatively little data from the covered stent era. In specialized centers, patients with BuddChiari syndrome and cirrhosis can nearly always be treated with a combination of endoscopy, interventional radiology, and liver transplantation (77). In those rare instances in which these therapies fail in patients with cirrhosis, sideto-side splenorenal shunt placement remains a good option. Percutaneous intervention is typically successful in managing shunt dysfunction, including thrombosis and stenosis (Fig  14) . In children, in whom extrahepatic portal vein occlusion is a relatively common cause of portal hypertension and bare stents may still be required, mesocaval or mesoportal shunts have demonstrated good long-term patency (78) .
Peritoneovenous Shunt
Drainage of peritoneal fluid into the systemic venous circulation through a tunneled catheter with a nonreturn valve and a subcutaneous control pump can be safely performed by interventional radiologists (79, 80) . Guidelines from the American Association for the Study of Liver Diseases recommend peritoneovenous shunt placement only in patients who are diuretic resistant and are not candidates for transplantation or serial therapeutic paracentesis. In addition, patients require sufficient cardiorespiratory and renal function to minimize fluid overload from shunting of ascites into the intravascular compartment. Complications have been reported in up to 30% of patients and include shunt occlusion (eg, fibrin sheath), infection, vena caval thrombosis, pulmonary edema, bleeding from varices, and disseminated intravascular coagulopathy.
In a randomized trial, bare stent TIPS showed significantly better assisted patency and ascites control than peritoneovenous shunts in the treatment of medically intractable ascites (81).
Arai et al (82) have recently described the use of a novel transjugular transhepatic peritoneovenous shunt in patients with malignant ascites, with access into the abdominal cavity via a TIPS needle. This technique avoids the long subcutaneous tunneling required for Denver shunt placement and may be less invasive and more advantageous if catheter exchange is needed (82) .
Conclusion
Interventional radiology can provide a number of image-guided procedures for the management of complications of portal hypertension in patients in whom archetypal TIPS placement has failed or is contraindicated. A careful review of individual pathophysiology, vascular anatomy, and hemodynamic flow patterns is crucial in selecting an appropriate intervention. 
